401 related articles for article (PubMed ID: 28256262)
21. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous Sebaceous Lesions in a Patient With MUTYH-Associated Polyposis Mimicking Muir-Torre Syndrome.
Kacerovska D; Drlik L; Slezakova L; Michal M; Stehlik J; Sedivcova M; Hadravsky L; Kazakov DV
Am J Dermatopathol; 2016 Dec; 38(12):915-923. PubMed ID: 27870730
[TBL] [Abstract][Full Text] [Related]
23. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome.
Entius MM; Keller JJ; Drillenburg P; Kuypers KC; Giardiello FM; Offerhaus GJ
Clin Cancer Res; 2000 May; 6(5):1784-9. PubMed ID: 10815898
[TBL] [Abstract][Full Text] [Related]
24. The role of immunohistochemistry in the Muir-Torre Syndrome.
Oliveira CM; Campos JG; Maia MR; Lobo LE; Valle FF
An Bras Dermatol; 2015; 90(3 Suppl 1):168-70. PubMed ID: 26312706
[TBL] [Abstract][Full Text] [Related]
25. [Lynch syndrome, Muir Torre variant: 2 cases].
Castro-Mujica Mdel C; Barletta-Carrillo C; Acosta-Aliaga M; Montenegro-Garreaud X
Rev Gastroenterol Peru; 2016; 36(1):81-5. PubMed ID: 27131946
[TBL] [Abstract][Full Text] [Related]
26. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
27. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.
Yanaba K; Nakagawa H; Takeda Y; Koyama N; Sugano K
Br J Dermatol; 2008 Jan; 158(1):150-6. PubMed ID: 17941949
[TBL] [Abstract][Full Text] [Related]
28. Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field.
Yozu M; Symmans P; Dray M; Griffin J; Han C; Ng D; Parry S; Wong K
Virchows Arch; 2013 Mar; 462(3):355-60. PubMed ID: 23299928
[TBL] [Abstract][Full Text] [Related]
29. Universal immunohistochemical screening of sebaceous neoplasms for Muir-Torre syndrome: Putting the cart before the horse?
Kim RH; Nagler AR; Meehan SA
J Am Acad Dermatol; 2016 Nov; 75(5):1078-1079. PubMed ID: 27745640
[No Abstract] [Full Text] [Related]
30. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
31. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.
Ponti G; Ponz de Leon M; Losi L; Di Gregorio C; Benatti P; Pedroni M; Scarselli A; Riegler G; Lembo L; Pellacani G; Seidenari S; Rossi G; Roncucci L
Br J Dermatol; 2005 Jun; 152(6):1335-8. PubMed ID: 15949004
[TBL] [Abstract][Full Text] [Related]
32. Muir-Torre syndrome: a variant of the cancer family syndrome.
Hall NR; Williams MA; Murday VA; Newton JA; Bishop DT
J Med Genet; 1994 Aug; 31(8):627-31. PubMed ID: 7815421
[TBL] [Abstract][Full Text] [Related]
33. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
34. Muir-Torre Syndrome with Novel Mutation in the MSH2 Gene.
Ustaoglu E; Agirgol S; Aymelek HS; Turhan EI
Acta Dermatovenerol Croat; 2023 Dec; 31(3):144-147. PubMed ID: 38439724
[TBL] [Abstract][Full Text] [Related]
35. Muir-Torre syndrome.
Cohen PR; Kohn SR; Davis DA; Kurzrock R
Dermatol Clin; 1995 Jan; 13(1):79-89. PubMed ID: 7712655
[TBL] [Abstract][Full Text] [Related]
36. [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].
Gilly B; Unholzer A; Strobl-Wildemann G; Haas C; Starz H; Welzel J
Hautarzt; 2013 Apr; 64(4):290-4. PubMed ID: 23229822
[TBL] [Abstract][Full Text] [Related]
37. Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?
Vaisfeld A; Calicchia M; Pomponi MG; Lucci-Cordisco E; Reggiani-Bonetti L; Genuardi M
Fam Cancer; 2019 Oct; 18(4):421-427. PubMed ID: 31292797
[TBL] [Abstract][Full Text] [Related]
38. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
39. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
Cohen PR; Kurzrock R
Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
[TBL] [Abstract][Full Text] [Related]
40. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
Rishi K; Font RL
Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
